ArticleHeliyon2024
Granulomatosis with polyangiitis involving both ischemic and hemorrhagic cerebrovascular disease: A case report and literature review.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Granulomatosis with polyangiitis (GPA) is a necrotizing small-vessel vasculitis associated with antineutrophilic cytoplasmic antibodies (ANCAs). GPA can have multisystem involvement; however, central nervous system (CNS) manifestations are uncommon. Here, for this first time, we report a rare case of GPA with both ischemic and hemorrhagic CNS involvement. Care presentation: A 67-year-old previously healthy male presented with intermittent fever, malaise, hemoptysis, skin lesions, and hearing loss. Chest computed tomography revealed multiple nodular lesions, which later enlarged and merged into consolidations. His serum ANCA titer was 1:80 with high PR3-ANCA activity. Methylprednisolone was initiated at a dose of 40 mg/day; however, only a partial response was observed. He complained dizziness and awkwardness in moving his left extremities during hospitalization, and subsequent imaging tests revealed ischemic attacks and intracranial hemorrhage in different locations. Steroid pulse therapy and rituximab were administered to induce remission. The neurological and pulmonary lesions resolved gradually. There were no signs of recurrence at 12 months post treatment. Conclusion: Our case highlights the involvement of CNS manifestations in GPA, and suggests potential role of rituximab in treatment of GPA patients with CNS involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.